NCT04648696Recruiting
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin in Outpatient Parenteral Antibiotic Therapy: a Prospective, Randomized Trial
Wake Forest University Health SciencesPhase 4ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Infection
- Drug/Device/Intervention
- Vancomycin CI
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Wake Forest University Health Sciences
- Location
- Winston-Salem, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Mar 03, 2021
- End date
- Oct 01, 2022
- Enrollment
- 200 participants
Primary outcome
Incidence of Nephrotoxicity
Summary
Evaluate the safety and outcomes associated between the two treatment modalities
ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsInfection following immunizationOther infectious diseasesViral infection, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04648696
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04648696 through Pure Global AI's free database. This Phase 4 trial is sponsored by Wake Forest University Health Sciences and is currently Recruiting. The study focuses on Infection. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.